Estrella Immunopharma公司已正式披露一项融资计划,将实施总额800万美元的注册直接发行,并同步开展私募配售。此次发行的定价将严格遵循纳斯达克市场规则,采用市价定价机制。该举措旨在为公司的免疫药物研发及业务拓展注入新的资金动力。
Estrella Immunopharma公司已正式披露一项融资计划,将实施总额800万美元的注册直接发行,并同步开展私募配售。此次发行的定价将严格遵循纳斯达克市场规则,采用市价定价机制。该举措旨在为公司的免疫药物研发及业务拓展注入新的资金动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.